Cyclic lysozyme administration as a tool for immunopotentiation in patients with multiple myeloma.
Fourteen patients with multiple myeloma (MM) were given chemotherapy courses for 7 days followed by 21-day intervals, combined with an immunomodulating treatment, namely lysozyme (LZM), 2 g daily for three weeks every other interval. Some parameters of cell-mediated immunity (total-E-rosettes, monocyte and polymorphonuclear leukocyte chemotaxis, skin tests) as well as humoral immunity (serum Ig levels, electrophoresis, immunoelectrophoresis) were evaluated comparatively in the intervals with and in those without LZM administration. A significant increase in total-E-rosettes and monocyte chemotaxis was observed in about half of the patients studied, this enhancement being accompanied by a reduction in both frequency and severity of viral and bacterial infections. No side-effects ascribable to LZM were recorded in any of the patients.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002634:Chemotaxis, Leukocyte; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007136:Immunoglobulins / Q000032:analysis; D017053:Infection Control; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000276:immunology; D009101:Multiple Myeloma / Q000188:drug therapy / Q000276:immunology*; D009113:Muramidase / Q000627:therapeutic use*; D009504:Neutrophils / Q000276:immunology; D012397:Rosette Formation; D012882:Skin Tests
D000276:Adjuvants, Immunologic; D007136:Immunoglobulins; D009113:Muramidase